ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, announced today that the U.S. Patent & Trademark Office has issued a new cancer patent (U.S. Patent 7,405,214) entitled, "Nucleoside Derivatives and Therapeutic Use Thereof," in support of the Company’s continued efforts to develop superior cancer treatments.
